Latest Regulated Markets News

Infotrust Ltd (ASX: ITS) reported a 9.8% rise in FY26 revenue to $64.1 million, powered by a strategic pivot to cyber security. The company exited its Cloud segment, repaid all bank debt, and acquired Catalyst Cyber to boost federal market presence, positioning for profitable growth in FY27.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Zinc of Ireland (ASX: ZMI) has fast-tracked its ARGO technology development to recover germanium, gallium, and indium, targeting early 2027 for pilot plant operations. The move aligns with EU regulatory demands for critical minerals and aims to reduce waste and emissions in zinc smelting.

SkyCity Entertainment Group reported a 22% drop in underlying EBITDA for FY26, impacted by regulatory costs and carded play rollout, while progressing asset sales and preparing for New Zealand's online casino market.

Light & Wonder's Q2 2026 sees net income jump 26% to $120 million, driven by strong Gaming and iGaming growth. The company sticks to its 2026 outlook, targeting mid- to high-single-digit EBITDA growth and aims to reduce leverage below 3.0x by mid-2027.

Unith Ltd boosted its AI digital human platform with ISO/IEC 27001:2022 certification, launched new SDKs, and secured $2.75 million in fresh capital to fuel growth and commercial expansion.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Dataworks Group has arranged a $1.5 million unsecured working capital facility with a three-month term and 18% interest, aiming to strengthen liquidity and support ongoing and new commercial contracts without diluting equity.

CleanSpace's AGILE respirator has achieved AS/NZS 17420.2:2021 certification, paving the way for commercialisation in Australia and New Zealand alongside its recent European approval.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.